SCHEMBL6469089

SCHEMBL6469089

NCC#Cc1cncnc1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 7/20 0.59
CYP2C19 P33261 6/20 0.59
CYP2E1 P05181 5/20 0.59
CYP2B6 P20813 5/20 0.59
CYP2D6 P10635 5/20 0.59
CYP3A4 P08684 4/20 0.59
CYP2C9 P11712 4/20 0.59
CYP1A2 P05177 5/20 0.57
CYP2C8 P10632 3/20 0.57
THPO P40225 1/20 0.48
GRM5 P41594 3/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
AOC1 P19801 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8922779 0.76 GRM5 (0.46) CYP2A6CYP2C19CYP2E1CYP2B6CYP2D6
SCHEMBL17050214 0.76 GRM5 (0.48) CYP2A6CYP2C19CYP2E1CYP2B6CYP2D6
SCHEMBL13907283 0.76 GRM5 (0.70) GRM5
SCHEMBL3603698 0.74 CYP2A6 (1.00) CYP2A6CYP2C19CYP2E1CYP2B6CYP2D6
SCHEMBL9257177 0.73 GRM5 (0.43) GRM5
SCHEMBL23781631 0.73 CYP2A6 (0.50) CYP2A6CYP2C19CYP2E1CYP2B6CYP2D6
SCHEMBL20409161 0.72
SCHEMBL4072436 0.71 CYP2C19 (0.60) CYP2A6CYP2C19CYP2E1CYP2B6CYP2D6
SCHEMBL6449000 0.71 CYP2C19 (0.75) CYP2A6CYP2C19CYP2E1CYP2B6CYP2D6
SCHEMBL14031029 0.70 CYP2C19 (0.47) CYP2A6CYP2C19CYP2E1CYP2B6CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210276987-A1 PHARMACEUTICAL AGENTS FOR USE IN SMOKING AND TOBACCO CESSATION WASHINGTON STATE UNIVERSITY (US) 2021-09-09 US disclosed
EP-1015643-B1 METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS AGILENT TECHNOLOGIES INC (US) 2005-09-21 EP disclosed
US-20040248104-A1 Methods and reagents for profiling quantities of nucleic acids AGILENT TECHNOLOGIES, INC. 2004-12-09 US disclosed
US-6218118-B1 MIXTURE OF NATURAL AND MASS-MODIFIED GENERIC OLIGONUCLEOTIDE PRECURSORS; USING MIXTURE AND ENZYMATIC PROCESSES TO ALTER THE LENGTH, AND THUS THE MASS, OF PRECURSORS THAT ARE COMPLEMENTARY TO TARGET NUCLEIC ACID AGILENT TECHNOLOGIES, INC. 2001-04-17 US disclosed
EP-1015643-A2 METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS Hewlett-Packard Company (US) 2000-07-05 EP disclosed
WO-2000003038-A2 METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS HEWLETT-PACKARD COMPANY (US) 2000-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210276987-A1 PHARMACEUTICAL AGENTS FOR USE IN SMOKING AND TOBACCO CESSATION CYP2A6, CYP2B6, CYP2D6 CYP2A6 1/4885CYP2C19 51/4885CYP2E1 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.